Drug Safety

3 years 10 months ago
Do we need to monitor #ECG in patients on #HCQ and #polypharmacy? Dr Antivalle reported ⬆️QTc interval in HCQ vs controls. Only 3/132 was above ULN in HCQ group though. Importantly,⬆️QTc was noted more in HCQ + co-meds (e.g. PPI) #EULAR2021 #POS0090 @RheumNow https://t.co/1Ui4MghqIk


3 years 10 months ago
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
⭐️No overall increase in all CA: RTX, TOCI
⭐️Abatacept 1.21HR for all cancer, mainly NMSC
⭐️needs more data on JAKs, IL-17, IL-23
Abs#6916
#EULAR2021 @RheumNow

3 years 10 months ago
Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?
⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID
⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w
🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA.
OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f


3 years 10 months ago
In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u
